MRUS: 23% | Merus shares are trading higher after the company announced the publication of an abstract regarding petosemtamab in combination with pembrolizumab on the 2024 ASCO Annual Meeting website.
GH: 25% | Guardant Health shares are trading higher after the company announced that the FDA Advisory Committee Panel recommends approval of Shield blood test for colorectal cancer screening.
DECK: 12% | Deckers Outdoor shares are trading higher after the company reported better-than-expected Q4 financial results.